Navigation Links
New Data Show That Herceptin, Xeloda and Avastin Help Patients With Early and Advanced Breast Cancer Live Longer or Remain Disease Free for Longer
Date:12/10/2008

BASEL, Switzerland, Dec. 10 /PRNewswire/ -- New data being presented at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) show that Herceptin (trastuzumab), Avastin (bevacizumab) and oral Xeloda (capecitabine) continue to offer new and better treatment options for breast cancer patients allowing women to live longer or remain disease-free for longer if the medicines are given before and after surgery as well as in advanced stages of disease.

    Key data being presented include:

    - Herceptin before surgery: Results from the NOAH (NeOAdjuvant Herceptin)
      phase III study showed that women with locally advanced HER2-positive
      breast cancer who started a combination of Herceptin and standard
      chemotherapy prior to surgery had a significantly greater chance of
      living free of their disease (event-free survival) three years after
      initiation of treatment as compared to women who were receiving pre-
      operative chemotherapy alone.

    - Xeloda in early breast cancer: Early data from an independent study in
      Finland and Sweden indicate that the chemotherapy pill Xeloda, which is
      already proven in advanced breast cancer, may also reduce the
      recurrence of early breast cancer and help women live longer. This is
      one of 20 Xeloda abstracts that have been accepted for presentation
      during SABCS.

    - Avastin in advanced breast cancer: First efficacy results from the
      largest ever safety study of Avastin in a real-life setting, which
      involved more than 2,000 patients with locally recurrent or metastatic
      breast cancer, confirm that Avastin can be used with a broad range of
      chemotherapy treatments giving patients a median of almost 10 months
      without their disease getting worse. The results, which are one of 24
      separate Avastin data presentations during SABCS, confirm that Avastin
      based therapy is essential for improving the li
'/>"/>
SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Positive Xeloda(R) Five-Year Overall Survival Study Data in the Adjuvant Treatment of Colon Cancer Presented at Leading European Cancer Meeting
5. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
6. Novel Xeloda(R) Dosing Schedule May Offer Well-Tolerated Alternative for Treatment of Advanced Breast Cancer
7. Nearly 60 New Studies of Oral Xeloda(R) (capecitabine) Featured at the 44th American Society of Clinical Oncology Annual Meeting
8. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
9. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
10. New Data Confirms That a Selective, Fully Human Anti-VEGF Antibody Being Developed by Peregrine is as Effective as Avastin(R) in Preclinical Cancer Models
11. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... Sept. 1, 2014 ... is available in its catalogue: Antibody ... http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... new class of therapeutic agents, gaining increasing attention ... addressed as the marriage of an antibody with ...
(Date:8/30/2014)... --  Royal Philips  (NYSE: PHG, AEX: PHIA) today announced ... system designed to enable global hospitals and health systems ... cost pressures. Making its debut at the  European Society ... this week, Affiniti provides innovative technology to ... deliver high quality patient care. "Affiniti ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products ... for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it has ... address a potential issue with a clip used ... Axilla application of the SAM Junctional Tourniquet (SJT).  ...
Breaking Medicine Technology:Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 2Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 3Philips Debuts New Affiniti Ultrasound System at the European Society of Cardiology Congress 2014 4SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
(Date:9/2/2014)... Kalamazoo, Michigan (PRWEB) September 02, 2014 ... of the Affordable Care Act and the Healthy Michigan ... Susan G. Komen remains a trusted funding resource for ... able to assist uninsured or underinsured women between the ... at or below 250 percent of the federal poverty ...
(Date:9/2/2014)... 02, 2014 At the 50th Annual ... will be an exhibitor at the Las Vegas Convention ... Vegas, NV 89109 Booth #374 Sept 19th and 20th ... healthy living through exercise, diet and supplementation. They pride ... provide the tools for all Prosupps customers to reach ...
(Date:9/2/2014)... Barcelona, Spain Tuesday 2 September 2014: Health ... heart failure guidelines, according to the results of ... Congress by Professor Aldo Maggioni. Clinical variables explained ... said: "This is a unique evaluation which combines ... countries. It provides a fuller picture of the ...
(Date:9/2/2014)... Attorney Robert M. Higgins has been ... Year" for Medical Malpractice Law - Plaintiffs. Higgins ... has been selected for inclusion in The Best Lawyers in ... practice area and designated metropolitan area is honored as the ... received during the peer-review assessments. , The Best ...
(Date:9/2/2014)... 02, 2014 AURO the ... announced today the expansion of its leadership team with ... Chief Financial Officer. Liang joins AURO in conjunction with ... will work closely with the operations, product management and ... cloud presence as well as ensuring effective internal and ...
Breaking Medicine News(10 mins):Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 2Health News:Local Affiliate of National Health Organization Continues 16-Year Tradition of Funding Programs to Help Fill Gaps in Breast Health Services for Under-Served Populations 3Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Health structures explain nearly 20 percent of non-adherence to heart failure guidelines 2Health News:Robert Higgins Named 2015 Best Lawyers® "Lawyer of the Year" in Boston 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 2Health News:AURO Appoints Kevin Liang as New Chief Financial Officer for Canadian Enterprise Public Cloud 3
... DENVER, July 31 Birner Dental Management,Services, Inc. ... dental practices,will conduct a conference call to review ... results, the teleconference may include,discussion of management,s expectations ... be held on Thursday, August 14, 2008 at ...
... 9% Increase In Revenues - - Florida Upholds Contract Award To Orchid ... ... - Regional Tender Work Underway In U.K. -, PRINCETON, N.J., ... identity DNA testing,services, today reported its financial results for the second quarter of,2008., ...
... Fla., July 31 NeoGenomics, Inc.,(OTC Bulletin Board: NGNM) today ... during the quarter included,the following:, Second Quarter 2008 ... 07 -- 17% sequential increase in revenue vs. Q1 ... initiative -- Average number of tests/requisition ...
... safety services, gained four new contracts in the second quarter, including ... awarded a significant contract expansion. , ... Little Falls, ... http://www.sentrx.com/drug_safety_services.shtml [drug safety __title__ drug safety] services, announced today ...
... QHR hospital client King,s Daughters Medical Center (KDMC) in ... grant as a part of the 2009 Health and ... by the Senate Appropriations Committee earlier this month. KDMC,s ... Wicker (Miss.), was initiated by QHR and its strategic ...
... The bestselling guide is now filled with new, essential information for knowing ... treatable disease. , ... Hoboken, NJ (PRWEB) July 31, 2008 -- Ever ... the book has been a major resource for those with diabetes and ...
Cached Medicine News:Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 2Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 3Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 4Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 5Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 6Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 7Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 8Health News:Orchid Cellmark Reports Second Quarter 2008 Financial Results 9Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 2Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 3Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 4Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 5Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 6Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 7Health News:NeoGenomics Announces Results for the Second Quarter of Fiscal Year 2008 8Health News:Sentrx Growth Continues with Four New Clients in Second Quarter 2Health News:Sentrx Growth Continues with Four New Clients in Second Quarter 3Health News:Healthcare Consulting Leader QHR, Strategic Health Care, Sen. Roger Wicker Partnership Yields $500,000 Grant for King's Daughters Medical Center 2Health News:Healthcare Consulting Leader QHR, Strategic Health Care, Sen. Roger Wicker Partnership Yields $500,000 Grant for King's Daughters Medical Center 3Health News:Diabetes For Dummies, 3rd Edition, Reports on the Latest Developments in the Field 2Health News:Diabetes For Dummies, 3rd Edition, Reports on the Latest Developments in the Field 3Health News:Diabetes For Dummies, 3rd Edition, Reports on the Latest Developments in the Field 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: